Illustrative image – not actual.
Sun Pharmaceutical Industries, a subsidiary of Sun Pharma has entered into a licensing agreement with Aclaris Therapeutics, a biopharmaceutical firm which specialises in innovative drug development for immuno-inflammatory diseases.
As per the pact, Aclaris grants Sun Pharma exclusive rights to specific patents for using deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, intended for treating alopecia areata (AA) or androgenetic alopecia (AGA).
The deal includes a USD 15 million initial payment, along with subsequent regulatory and commercial milestones, as well as royalties.
